Since 2021, Matt has been included in the prestigious IAM Strategy 300, which recognizes leaders in IP strategy and value creation worldwide.
Overview
Matt Bodenstein is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group with expertise in the chemical, pharmaceutical, food science, material science, and biotechnology spaces. He is recognized by his clients and peers as a leading patent strategist and is well-known for his thoughtful and creative approaches to obtaining business-critical patents suitable for immediate enforcement.
Matt’s technological expertise includes, but is not limited to, small molecule pharmaceuticals/new chemical entities (NCEs) and their uses, chemical synthesis, pharmaceutical formulations (including solid and liquid oral dosage forms, IV formulations, and transdermal/topical formulations), transdermal patches, polymorphs, deuterated analogs, in vivo and in vitro biochemical senor technology, chemical complexes, colloids, encapsulation, and new materials (such as protein/polymer alloys).
In each of these areas, Matt is an expert at creating and effectively and efficiently prosecuting global patent portfolios, all with an eye toward maximizing patent term and regulatory exclusivity. Matt also regularly conducts interviews with USPTO examiners, conducts and manages complex due diligence investigations in connection with potential investments, acquisitions, and licensing opportunities, and renders freedom to operate, validity, and non-infringement opinions. Matt and his team also regularly prepare and file Patent Term Extension (PTE) applications.
Given the breadth of Matt’s practice, he and his team are intimately familiar with the rigors of, and requirements for, prosecuting around the world. As a result, Matt’s applications take into account not only the requirements of U.S. patent practice, but also the strict and unforgiving requirements for support in ex-U.S. jurisdictions.
Matt is also an expert at drafting and negotiating term sheets, license agreements, and other strategic transactions/agreements.
Prior to joining Sterne Kessler, Matt was Intellectual Property Counsel for the former Medicis Pharmaceutical Corp., and an associate and patent agent in the IP Group of an AmLaw 100 law firm.
Before becoming a lawyer, Matt worked in the CNS Medical Chemistry group at Pfizer, Inc. and the Process Research and Development Group at Merck & Co., Inc.
Matt earned his J.D., cum laude, from Temple University Beasley School of Law, and his M.S. and B.A. degrees in Chemistry, from the University of Pennsylvania.
Outside of work, Matt can often be found walking his Great Pyrenees/hound mix, Ripley, relaxing with his family at a Nats or D.C. United game, or cranking away on his bike (look for him on Zwift!).
Education
- J.D., Temple University Beasley School of Law, cum laude
- M.S., Organic Chemistry, University of Pennsylvania
- B.A., Chemistry, University of Pennsylvania